Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK

Rajith K.R. Rajoli, Charles Williams Flexner, Justin Chiong, Andrew Owen, Ryan F. Donnelly, Eneko Larrañeta, Marco Siccardi

Research output: Contribution to journalArticle

Abstract

Introduction: Existing HIV therapy using oral antiretrovirals (ARVs) can result in pill fatigue and sub-optimal adherence. Microneedle array patches (MAPs) offer non-invasive, blood-free and painless drug delivery, and may improve patient adherence. The objective of this study was to develop a novel physiologically-based pharmacokinetic (PBPK) model to simulate the systemic pharmacokinetics of cabotegravir and rilpivirine MAPs using the intradermal route. Methods: The developed PBPK models were qualified against observed pharmacokinetic data after intramuscular (IM) and intradermal administration of long-acting nanoformulated rilpivirine to rats, and for IM administration of both drugs to healthy adults. Qualified models were then utilised to estimate suitable MAP characteristics (e.g. nanoformulation dose and release rates) and inform dosing strategies to maintain plasma concentrations above target trough concentrations for the designated dosing interval. Results: PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 180 mg for long-acting formulated cabotegravir between the release rates of 1 × 10−3–3 × 10−3h−1 and 1 × 10−3–1.5 × 10−3h−1 respectively, for a 70 kg adult. Estimated patch size was 60 cm2 for a 360 mg dose of cabotegravir. For q4-weekly dosing, rilpivirine required a 1080 mg loading dose and a 540 mg maintenance dose with release rates of 1.5 × 10−3–2.5 × 10−3h−1 and 5 × 10−4–1 × 10−3h−1, respectively. Weekly dosing was also evaluated to assess the potential application from a smaller patch size. The ability to self-administer via a patch that is only left in place for a short duration makes longer durations less important than for some other long-acting approaches. Weekly cabotegravir required 60 mg between release rates 7 × 10−3–9 × 10−3h−1 and rilpivirine required 270 mg and 180 mg respectively between release rates of 7 × 10−3–9 × 10−3h−1. Discussion: This model estimated optimal dose and release rates for cabotegravir and rilpivirine MAPs. Our approach provides a computational platform to support rational development of intradermal administration strategies to tackle problems associated with chronic oral ARV administration.

Original languageEnglish (US)
Pages (from-to)101-109
Number of pages9
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume144
DOIs
StatePublished - Nov 1 2019

Fingerprint

Rilpivirine
Pharmacokinetics
Aptitude
Patient Compliance
Pharmaceutical Preparations
Fatigue
Oral Administration
HIV

Keywords

  • Antiretroviral
  • Intradermal
  • Long-acting
  • Microneedle
  • Patch
  • PBPK

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Cite this

Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. / Rajoli, Rajith K.R.; Flexner, Charles Williams; Chiong, Justin; Owen, Andrew; Donnelly, Ryan F.; Larrañeta, Eneko; Siccardi, Marco.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 144, 01.11.2019, p. 101-109.

Research output: Contribution to journalArticle

Rajoli, Rajith K.R. ; Flexner, Charles Williams ; Chiong, Justin ; Owen, Andrew ; Donnelly, Ryan F. ; Larrañeta, Eneko ; Siccardi, Marco. / Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. In: European Journal of Pharmaceutics and Biopharmaceutics. 2019 ; Vol. 144. pp. 101-109.
@article{7d74c6913708429f9e413dbbf7f4185e,
title = "Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK",
abstract = "Introduction: Existing HIV therapy using oral antiretrovirals (ARVs) can result in pill fatigue and sub-optimal adherence. Microneedle array patches (MAPs) offer non-invasive, blood-free and painless drug delivery, and may improve patient adherence. The objective of this study was to develop a novel physiologically-based pharmacokinetic (PBPK) model to simulate the systemic pharmacokinetics of cabotegravir and rilpivirine MAPs using the intradermal route. Methods: The developed PBPK models were qualified against observed pharmacokinetic data after intramuscular (IM) and intradermal administration of long-acting nanoformulated rilpivirine to rats, and for IM administration of both drugs to healthy adults. Qualified models were then utilised to estimate suitable MAP characteristics (e.g. nanoformulation dose and release rates) and inform dosing strategies to maintain plasma concentrations above target trough concentrations for the designated dosing interval. Results: PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 180 mg for long-acting formulated cabotegravir between the release rates of 1 × 10−3–3 × 10−3h−1 and 1 × 10−3–1.5 × 10−3h−1 respectively, for a 70 kg adult. Estimated patch size was 60 cm2 for a 360 mg dose of cabotegravir. For q4-weekly dosing, rilpivirine required a 1080 mg loading dose and a 540 mg maintenance dose with release rates of 1.5 × 10−3–2.5 × 10−3h−1 and 5 × 10−4–1 × 10−3h−1, respectively. Weekly dosing was also evaluated to assess the potential application from a smaller patch size. The ability to self-administer via a patch that is only left in place for a short duration makes longer durations less important than for some other long-acting approaches. Weekly cabotegravir required 60 mg between release rates 7 × 10−3–9 × 10−3h−1 and rilpivirine required 270 mg and 180 mg respectively between release rates of 7 × 10−3–9 × 10−3h−1. Discussion: This model estimated optimal dose and release rates for cabotegravir and rilpivirine MAPs. Our approach provides a computational platform to support rational development of intradermal administration strategies to tackle problems associated with chronic oral ARV administration.",
keywords = "Antiretroviral, Intradermal, Long-acting, Microneedle, Patch, PBPK",
author = "Rajoli, {Rajith K.R.} and Flexner, {Charles Williams} and Justin Chiong and Andrew Owen and Donnelly, {Ryan F.} and Eneko Larra{\~n}eta and Marco Siccardi",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.ejpb.2019.09.011",
language = "English (US)",
volume = "144",
pages = "101--109",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",

}

TY - JOUR

T1 - Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK

AU - Rajoli, Rajith K.R.

AU - Flexner, Charles Williams

AU - Chiong, Justin

AU - Owen, Andrew

AU - Donnelly, Ryan F.

AU - Larrañeta, Eneko

AU - Siccardi, Marco

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Introduction: Existing HIV therapy using oral antiretrovirals (ARVs) can result in pill fatigue and sub-optimal adherence. Microneedle array patches (MAPs) offer non-invasive, blood-free and painless drug delivery, and may improve patient adherence. The objective of this study was to develop a novel physiologically-based pharmacokinetic (PBPK) model to simulate the systemic pharmacokinetics of cabotegravir and rilpivirine MAPs using the intradermal route. Methods: The developed PBPK models were qualified against observed pharmacokinetic data after intramuscular (IM) and intradermal administration of long-acting nanoformulated rilpivirine to rats, and for IM administration of both drugs to healthy adults. Qualified models were then utilised to estimate suitable MAP characteristics (e.g. nanoformulation dose and release rates) and inform dosing strategies to maintain plasma concentrations above target trough concentrations for the designated dosing interval. Results: PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 180 mg for long-acting formulated cabotegravir between the release rates of 1 × 10−3–3 × 10−3h−1 and 1 × 10−3–1.5 × 10−3h−1 respectively, for a 70 kg adult. Estimated patch size was 60 cm2 for a 360 mg dose of cabotegravir. For q4-weekly dosing, rilpivirine required a 1080 mg loading dose and a 540 mg maintenance dose with release rates of 1.5 × 10−3–2.5 × 10−3h−1 and 5 × 10−4–1 × 10−3h−1, respectively. Weekly dosing was also evaluated to assess the potential application from a smaller patch size. The ability to self-administer via a patch that is only left in place for a short duration makes longer durations less important than for some other long-acting approaches. Weekly cabotegravir required 60 mg between release rates 7 × 10−3–9 × 10−3h−1 and rilpivirine required 270 mg and 180 mg respectively between release rates of 7 × 10−3–9 × 10−3h−1. Discussion: This model estimated optimal dose and release rates for cabotegravir and rilpivirine MAPs. Our approach provides a computational platform to support rational development of intradermal administration strategies to tackle problems associated with chronic oral ARV administration.

AB - Introduction: Existing HIV therapy using oral antiretrovirals (ARVs) can result in pill fatigue and sub-optimal adherence. Microneedle array patches (MAPs) offer non-invasive, blood-free and painless drug delivery, and may improve patient adherence. The objective of this study was to develop a novel physiologically-based pharmacokinetic (PBPK) model to simulate the systemic pharmacokinetics of cabotegravir and rilpivirine MAPs using the intradermal route. Methods: The developed PBPK models were qualified against observed pharmacokinetic data after intramuscular (IM) and intradermal administration of long-acting nanoformulated rilpivirine to rats, and for IM administration of both drugs to healthy adults. Qualified models were then utilised to estimate suitable MAP characteristics (e.g. nanoformulation dose and release rates) and inform dosing strategies to maintain plasma concentrations above target trough concentrations for the designated dosing interval. Results: PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 180 mg for long-acting formulated cabotegravir between the release rates of 1 × 10−3–3 × 10−3h−1 and 1 × 10−3–1.5 × 10−3h−1 respectively, for a 70 kg adult. Estimated patch size was 60 cm2 for a 360 mg dose of cabotegravir. For q4-weekly dosing, rilpivirine required a 1080 mg loading dose and a 540 mg maintenance dose with release rates of 1.5 × 10−3–2.5 × 10−3h−1 and 5 × 10−4–1 × 10−3h−1, respectively. Weekly dosing was also evaluated to assess the potential application from a smaller patch size. The ability to self-administer via a patch that is only left in place for a short duration makes longer durations less important than for some other long-acting approaches. Weekly cabotegravir required 60 mg between release rates 7 × 10−3–9 × 10−3h−1 and rilpivirine required 270 mg and 180 mg respectively between release rates of 7 × 10−3–9 × 10−3h−1. Discussion: This model estimated optimal dose and release rates for cabotegravir and rilpivirine MAPs. Our approach provides a computational platform to support rational development of intradermal administration strategies to tackle problems associated with chronic oral ARV administration.

KW - Antiretroviral

KW - Intradermal

KW - Long-acting

KW - Microneedle

KW - Patch

KW - PBPK

UR - http://www.scopus.com/inward/record.url?scp=85072264262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072264262&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2019.09.011

DO - 10.1016/j.ejpb.2019.09.011

M3 - Article

C2 - 31525446

AN - SCOPUS:85072264262

VL - 144

SP - 101

EP - 109

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -